WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient

European Journal of Haematology

Volumn 85, Issue 4, 2010, Pages 358-360

  Oji, Yusuke ^a   Oka, Yoshihiro ^a   Nishida, Sumiyuki ^a   Tsuboi, Akihiro ^a   Kawakami, Manabu ^a   Shirakata, Toshiaki ^a   Takahashi, Kazuko ^a   Murao, Ayako ^a   Nakajima, Hiroko ^a   Narita, Miwako ^b   Takahashi, Masuhiro ^b   Morita, Satoshi ^c   Sakamoto, Junichi ^d   Tanaka, Toshio ^a   Kawase, Ichiro ^a   Hosen, Naoki ^a   Sugiyama, Haruo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CML; Imatinib; immunotherapy; WT1 peptide vaccine

Indexed keywords

BCR ABL PROTEIN; HLA A ANTIGEN; IMATINIB; MONTANIDE ISA 51; PEPTIDE VACCINE; UNCLASSIFIED DRUG; WT1 PEPTIDE VACCINE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CANCER VACCINE; MESSENGER RNA; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; SUBUNIT VACCINE; WT1 PROTEIN;

ADJUVANT THERAPY; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CD8+ T LYMPHOCYTE; CELL DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; ERYTHEMA; FEMALE; HUMAN; HYPERSENSITIVITY; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VACCINATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG RESISTANCE; IMMUNOLOGY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

AGED; ANTINEOPLASTIC AGENTS; CANCER VACCINES; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM, RESIDUAL; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT; WT1 PROTEINS; BENZAMIDES;

EID: 77956955626     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01497.x     Document Type: Article

References (8)

1. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003 349 : 1423 1432.
2. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007 109 : 58 60.
3. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004 101 : 13885 13890.
4. Hosen N, Shirakata T, Nishida S, et al. The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis. Leukemia 2007 21 : 1783 1791.
5. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994 84 : 3071 3079.
6. Loriaux M, Deininger M. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma 2004 45 : 2197 2203.
7. Kovitz C, Kantarjian H, Garcia-Manero G, et al. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006 108 : 2811 2813.
8. Kawakami M, Oka Y, Tsuboi A, et al. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 μg/body) in a patient with chronic myelomonocytic leukemia. Int J Hematol 2007 85 : 426 429.